Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ) that was first approved in December of 2021 for severe asthma in adult and pediatric patients 12 years and older. A single-use, self-administrated version was approved in 2023. In late 2025, Tezspire was also approved for chronic rhinosinusitis with nasal polyps.
Read on to learn more about Tezspire, including its warnings and precautions, dosage and administration information, and more.
Medication Overview:
- Brand Name: Tezspire
- Generic Name: tezepelumab-ekko
- Treatment for: Severe Asthma, Chronic Rhinosinusitis with Nasal Polyps
- Manufacturer: AstraZeneca
- Initial FDA Approval: December 2021
| Indicated Condition | Indication | Age | Approval Date |
|---|---|---|---|
| Severe Asthma | Indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. | 12 and Older | December 2021 |
| Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). | 12 and Older | October 2025 |
Warnings and Precautions:
- Hypersensitivity Reactions: Hypersensitivity reactions have been observed in the clinical trials (e.g., rash, allergic conjunctivitis) following the administration of Tezspire. Postmarketing cases of anaphylaxis have been reported. Initiate appropriate treatment as clinically indicated in the event of a hypersensitivity reaction.
- Risk Associated with Abrupt Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with Tezspire. Decrease corticosteroids gradually, if appropriate.
- Parasitic (Helminth) Infection: Treat patients with pre-existing helminth infections before therapy with Tezspire. If patients become infected while receiving Tezspire and do not respond to anti-helminth treatment, discontinue Tezspire until the parasitic infection resolves.
- Vaccination: Avoid use of live attenuated vaccines.
Dosage and Administration:
- Recommended dosage is 210 mg administered once every four weeks.
- Administer by subcutaneous injection.
- See full prescribing information for preparation and administration instructions.
Contraindications:
Known hypersensitivity to tezepelumab-ekko or excipients.
Drug Interactions:
No formal drug interaction studies have been performed with Tezspire.
Adverse Reactions:
Most common adverse reaction (incidence ≥3%) are:
- Asthma: pharyngitis, arthralgia, and back pain.
- Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia.
Example of tezepelumab in a Clinical Practice Guideline
- Biologic Management in Severe Asthma for Adults
- American College of Chest Physicians (CHEST), September 2025
- “In adult patients with severe asthma who have not demonstrated a clinical response to dupilumab after 4-6 months, the panel suggests either anti-IL5/5Rα or tezepelumab. In steroid dependent patients, the panel suggests anti-IL5/5Rα over tezepelumab.”
Please note: This article is current as of April 2, 2026. Consult our clinical guidelines library or drug information tool to ensure you always have the most up-to-date information.
Sign up for alerts to keep up with the latest clinical guidelines and guideline updates.